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Abstract Pharmacodynamic modeling of pulsatile
endogenous compounds (e.g. growth hormone [GH]) is
currently limited to the identification of a low number of
pulses. Commonly used pharmacodynamic models are not
able to capture the complexity of pulsatile secretion and
therefore non-compartmental analyses are performed to
extract summary statistics (mean, AUC, Cmax). The aim of
this study was to develop a new quantification method that
deals with highly variable pulsatile data by using a
deconvolution-analysis-informed population pharmacody-
namic modeling approach. Pulse frequency and pulse times
were obtained by deconvolution analysis of 24 h GH pro-
files. The estimated pulse times then informed a non-linear
mixed effects population pharmacodynamic model in
NONMEM V7.3. The population parameter estimates were
used to perform simulations that show agonistic and
antagonistic drug effects on the secretion of GH. Addi-
tionally, a clinical trial simulation shows the application of
this method in the quantification of a hypothetical drug
effect that inhibits GH secretion. The GH profiles were
modeled using a turnover compartment in which the
baseline secretion, kout, pulse secretion width, amount at
time point 0 and pulse amplitude were estimated as pop-
ulation parameters. Population parameters were estimated
with low relative standard errors (ranging from 2 to 5%).
Total body water (%) was identified as a covariate for pulse
amplitude, baseline secretion and the pulse secretion width
following a power relationship. Simulations visualized
multiple gradients of a hypothetical drug that influenced
the endogenous secretion of GH. The established model
was able to fit and quantify the highly variable individual
24 h GH profiles over time. This pharmacodynamic model
can be used to quantify drug effects that target other
endogenous pulsatile compounds.
Keywords Population PK/PD modeling  Growth
hormone  Deconvolution analysis  Pulsatile secretion
Introduction
Many drugs exhibit wanted and/or unwanted effects on the
secretion of endogenous pituitary hormones such as growth
hormone (GH), prolactin or luteinizing hormone (LH).
These hormones are secreted in ‘bursts’ or pulses and,
particularly in the case of GH, vary in amplitude, time of
secretion and may be influenced by circadian rhythmicity
and sleep [1–4]. When studying drug effects on the
secretion of GH, a non-compartmental analysis on the
plasma concentration–time profile is commonly performed.
This results in mean and maximum plasma GH concen-
trations over a specified time interval or the area under the
plasma GH concentration–time curve (AUC) to be used for
comparison between groups [5–7]. Importantly, by reduc-
ing the complex concentration–time profile of GH to
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summary statistics, the use of time as a continuous variable
is lost. Therefore, the analysis results are highly dependent
on the timeframe of observations and sampling interval,
e.g. the endogenous GH AUC of 0–12 h can yield different
results than the AUC of 12–24 h within the same indi-
vidual due to the secretion of variable pulses. This con-
tributes to high variability in these summary statistics.
Furthermore, the commonly used single GH measurement
or multiple-point mean [8, 9] does not capture the total
secretion profile of an individual and thereby limits the
correct quantification of a possible drug effect over time.
More advanced analysis methods, such as deconvolution
analysis, have been developed to extract more information
from a pulsatile profile [10, 11]. With deconvolution
analysis, the observed concentrations are treated as the
product of secretion and elimination processes. The
underlying pulsatile secretion processes are estimated as
Gaussian shaped events. The time points of these events are
optimized to fit the data via multiple in- and exclusion
steps [3, 10, 12]. Deconvolution analysis provides infor-
mation on the regularity, the frequency, the amplitude,
baseline secretion and the secretion width of pulses on an
individual level [12, 13]. Even though this increases the
amount of information that is retrieved from pulsatile GH
concentration–time profiles, time cannot be used as a
continuous variable in the reported tables. Thus, decon-
volution results are still dependent on the study design, and
it therefore has limited utility in comparing results between
studies where different dosing regimens or study designs
are used.
In drug development, population approach non-linear
mixed effects (NLME) models are often used to study the
pharmacokinetics and pharmacodynamics (PK/PD) of
drugs over time. For example, direct effect, turnover or
pool models are commonly used to describe endogenous
pituitary hormone secretion over time [14–16]. However,
such pharmacodynamic models cannot account for a highly
variable pulsatile secretion. In the literature, the imple-
mentation of pulsatile functions in NLME models has been
limited to compounds with a low number of pulses (me-
latonin [17], LH [2], ACTH [18]). When a higher number
of pulses is observed, the numerical complexity of the
model increases and the model stability decreases when the
pulse location, duration and amplitude of multiple pulses
need to be estimated.
The aim of this study is to develop a new method to
quantify and model pulsatile data for the development of a
pharmacodynamic model that is able to quantify highly
variable pulsatile secretion patterns over time by combin-
ing deconvolution analysis techniques and NLME model-
ing. Deconvolution analysis was previously performed on
data from a clinical study where GH concentrations were
sampled every 10 min over a 24 h period in normal weight,
upper body obese (UBO) women with large visceral fat
areas and lower body obese (LBO) women with small
visceral fat areas, before and after weight loss [19]. This
resulted in the identification of reduced GH secretion in
UBO subjects and no significant difference in GH half-life
or volume of distribution. This densely sampled and highly
variable dataset was used for the model development of
this study. The deconvolution method used in the study of
Pijl et al. [19] has been improved and applied in a new
software package, AutoDecon, which was implemented in
this study [3]. Furthermore, GH concentration–time pro-
files after the administration of hypothetical drugs that have
antagonistic or agonistic properties were simulated. As a
proof of concept of the application of this method on the
quantification of a drug effect, a simulated drug effect was
re-estimated using data from a clinical trial simulation.
Methods
Study design
Data were obtained from a clinical study which has been
reported previously [19]. In short, 16 women (8 UBO and 8
LBO subjects) followed a weight loss diet to study GH
kinetics, before and after weight loss, compared to normal
weight control subjects (N = 8). Blood samples for GH
analysis were taken at 10 min intervals for 24 h, resulting
in a maximum of 144 samples per individual per occasion.
The lower limit of quantification (LLOQ) for the GH
immunofluorometric assay was 0.03 mU/L.
Deconvolution analysis
Individual deconvolution analysis of the 24 h GH con-
centration time profiles was performed in AutoDecon [3].
This software provides a ‘‘nonsubjective, standardized, and
completely automated algorithm’’ [3] for the analysis of
pulsatile profiles. During data assembly, the expected
measurement times with 10 min intervals were used, as this
program requires regularly spaced time input. Separate data
files were created for each individual in which the mean
GH observation of the duplicate measurement, the standard
error of the mean and the number of analysis replicates for
each time point were included. The previously reported
coefficient of variation of the observations over the con-
centration range was used to calculate the standard error of
the mean for each observation [10, 19]. For AutoDecon to
function, initial estimates of the secretion width and an
initial half-life of GH (5 and 15 min, respectively) were
used as input. These parameters were optimized for each
individual during the deconvolution analysis. The
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convolution integral that is implemented in AutoDecon is
depicted in Eq. 1 [3].
C tð Þ ¼ r
t
0
Sn sð ÞE t  sð Þdsþ C 0ð ÞEðtÞ ð1Þ
where C(t) is the GH concentration over time, consisting of
the integral of all secretion events (Sn(s)), plus the con-
centration at time point zero (C(0)). The elimination
function (E) can follow a 1- or 2-compartment disposition
for GH, determined in AutoDecon.
Deconvolution analysis resulted in the estimation of an
individual’s pulse frequency, pulse times, secretion width,
baseline secretion, pulse amplitude and half-life. After
deconvolution analysis, statistical comparison of the results
between the LBO and UBO groups compared to normal
weight control subjects was done using an independent
2-group t test.
Model development
For each individual, the pulse frequency and the individual
pulse times, retrieved from the deconvolution analysis,
were included in the dataset for NLME modeling (NON-
MEM V7.3 [20]). The random effects structure was
incorporated in the model by a ln-normal transformation of
the random effects (g) on the population parameters [21].
Significant inter-individual variability (IIV) on population
parameters was included in the model following a forward
inclusion method (p\ 0.05). The residual error distribu-
tion (e) was drawn using an additive, proportional or
combined (additive and proportional) residual error struc-
ture using parameters from a normal distribution. Various
types of variance–covariance matrices were tested for the
correlation between the random effects when identified by
Pearson correlation plots. Due to high IIV and intra-indi-
vidual variability in the height of the pulses (pulse ampli-
tude) within a 24 h concentration–time profile, each pulse
was estimated as a different occasion (BOV) which
enabled the estimation of GH pulses of different heights
within one individual. The amplitude of a pulse was
modeled according to Eq. 2.
Amplituden ¼ hpopulation  e gþjnð Þ ð2Þ
where Amplituden is the amplitude of pulse n, hpopulation is
the population amplitude parameter, g is the random effects
distribution of the IIV and jn is the BOV, the intra-indi-
vidual variability, for pulse n.
Two equations (Eqs. 3, 4) were tested to fit a pulsatile
event in the NLME model. Equation 3 is adapted from the
documentation of AutoDecon [3], Eq. 4 is adapted from a
previous publication that models a single Gaussian shaped
pulse in NONMEM [2].
SnðtÞ ¼ eln Amplitudenð Þ12
tPulseTimen
SecretionSDð Þ2 ð3Þ
SnðtÞ ¼ Amplituden
tPulseTimen
SecretionSD
 exponentþ1
ð4Þ
where Sn(t) is the secretion over time for pulse n, Ampli-
tuden is the amplitude of pulse n, PulseTimen is the time
which corresponds with the maximum secretion time for
pulse n (retrieved from deconvolution analysis), and Se-
cretionSD corresponds with the width of the pulses. In
Eq. 3, the exponential transformation limits the Sn(t) to
positive values only. In Eq. 4, the exponents 2 and 4 were
evaluated during model development.
Covariates
The following covariates were explored: weight, height,
age, lean body mass (LBM), total body water (TBW), total
body fat, percentage fat mass, percentage LBM and per-
centage TBW. All weight related covariates were calcu-
lated using Bioelectrical Impedance Analysis (Bodystat
1500, Bodystat Ltd., Isle of Man, UK). Covariate rela-
tionships were explored using visual exploration of the
Pearson correlation plots and their correlation coefficients.
When a correlation coefficient was 0.5 or higher, covariate
relationships were formally tested for significance in the
structural model using linear, power and exponential rela-
tionships. Circadian rhythmicity was explored as a
covariate on the Amplitude parameter using a cosine
function with a 24 h acrophase or as a day/night effect.
Covariates were included using a forward inclusion method
(p\ 0.05) combined with backward elimination
(p\ 0.01) and centered around their mean values.
Model evaluation
Models were evaluated on basis of objective function value
(OFV, which approximates -2*Log Likelihood), goodness
of fit (GOF) plots and numerical evaluation [22]. Model
hypothesis testing was done under the assumption that the
difference in OFV is v2-distributed with the degrees of
freedom determined by the number of additional parame-
ters in the more complex model. A drop in OFV of more
than 3.84 points (p = 0.05) resulted in accepting the model
with one additional degree of freedom. For backward
elimination of a covariate, an increase of less than 6.6
points in OFV (p = 0.01) was needed for exclusion. Model
comparison implementing Eqs. 3 and 4 was done using the
Bayesian information criterion (BIC) due to changes in the
structural model. GOF plots consisted of population- and
individual model predictions versus observations, condi-
tional weighted residuals with interaction (CWRESI)
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versus clock time and population predictions. Numerical
evaluation was based on the relative standard error (RSE)
for population parameters, normalized prediction distribu-
tion error (NPDE) analysis, coefficient of variation for
random effects (CV%) and the condition number [22, 23].
Simulation
Multiple simulations with the developed model were per-
formed to visualize the effect of hypothetical drugs on the
GH concentration–time profile targeting GH secretion. For
these simulations, the parameter estimates of the developed
model were used to simulate a typical individual with a
pulse interval of 1.57 h (estimated mean pulse interval).
The half-life of the hypothetical drug was fixed to 6 h to
simulate a short-term effect which can still be observed in a
24 h period. The drug effect was implemented using an
Emax relationship driven by the amount of the hypothetical
drug where the maximum effect was reached immediately
after bolus dose administration (10 mg). The effect of the
drug on the pulsatile secretion was modeled using Eqs. 5
and 6.
Effect tð Þ ¼ Emax  AðtÞ
c
EA
c
50 þ AðtÞc
ð5Þ
Sn tð Þ ¼ eln Amplitudenð Þ12ð
tPulseTimen
SecretionSD
Þ2  ð1þ EffectðtÞÞ ð6Þ
where Emax varied between -1 and 10 to simulate inhibi-
tory and stimulatory effects and was 0 for simulations of
the typical individual. A(t) is the amount of the hypothet-
ical drug remaining in the body. For simulations of the
inhibitory drug effect, the Emax was equal to -1, -0.75 and
0. For simulations of the stimulatory drug effect, the Emax
was equal to 0, 2, 5 and 10. EA50 was fixed to 2 mg with c
equal to 5 to simulate a relatively fast offset of the drug
effect within 18 h after dosing. Covariate relationships
were simulated at their mean values.
A new clinical trial was simulated to investigate whether
the applied drug effects could be correctly re-estimated
using the developed method proposed in this study. Sim-
ulations were performed including the identified IIV and
residual error structure of the developed model. Pulses
were simulated at regular time intervals. Additionally, a
CV% of 10% was added on the EA50. A total of 5 cohorts
of 8 subjects were simulated (placebo, 2.5, 5, 7.5 and
10 mg) with an Emax of -0.9 (inhibiting the GH secretion
by 90%) and an EA50 of 3 mg with c equal to 5. The
parameters estimated in the deconvolution-analysis-in-
formed population model were fixed to their corresponding
values. The re-estimated drug effect parameters were then
compared to the simulated ‘true’ model values to judge the
ability to correctly recover the drug effect given this true
model.
Software
All data transformations, statistical tests on the deconvo-
lution results, visualizations and NPDE analysis were
performed using R (V3.2.2) [24] in conjunction with R
Studio (V0.99.887) [25]. AutoDecon (V20090124) [3] was
used for the deconvolution analysis of individual 24 h GH
profiles. NLME modeling was performed in NONMEM
V7.3 [20]. The BIC was calculated using Pirana (V2.9.0)
[26], no changes to the default BIC calculations were
made.
Results
A total of 2 subjects (1 from the LBO and 1 from the UBO
group) did not complete the occasion after weight loss. For
these individuals, only data from the visit before weight
loss were included in model development. Data below the
LLOQ (n = 52,\1%) were excluded from this analysis. A
total of 5377 GH observations were used for model
development. Figure 1 visualizes the GH concentration–
time profiles during the 24 h observation period for three
individuals. High intra- and inter-individual variability can
be observed in the pulse amplitude and the time of GH
secretion.
Deconvolution
Table 1 shows the summary of the deconvolution analysis
results for each group, before and after weight loss. A
1-compartment elimination function was identified as the
best fit for GH disposition. The secretion width of the
pulses was found to be significantly lower in LBO subjects
before weight loss and in all UBO subjects compared to
normal weight subjects. The UBO subjects before weight
loss showed a reduction in the baseline secretion compared
to normal weight subjects. No significant differences in the
pulse frequency, half-life, amplitude or pulse interval were
identified between normal weight and obese subjects.
Model development
The GH observations were best described using a turnover
compartment, as depicted in Fig. 2. The baseline secretion
was modeled as a steady-state condition, using a continu-
ous zero-order input (kin) in the central compartment and
first-order elimination (kout) that describes the elimination
of GH from the body. The kin was estimated as Baseline 
kout so that the Baseline parameter is estimated as mU/L.
The pulsatile secretion is the sum of the secretion of all
pulses at a certain time point (Eq. 7) where npulses is the
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pulse frequency of an individual. The differential equation
of the central GH compartment is presented in Eq. 8.
S tð Þ ¼ S1 tð Þ þ S2 tð Þ þ . . . þ Snpulses tð Þ ð7Þ
dðGHÞ
dt
¼ kin þ SðtÞ  kout  GH ð8Þ
A large proportion of the subjects showed GH concen-
trations above baseline at the start of the measurement
period (e.g. Figure 1, black line) due to the secretion of an
endogenous pulse of GH prior to the start of the observa-
tion period. To account for these initial concentrations, the
central compartment was initialized at an initial concen-
tration (A_0). The estimation of BOV between the GH
profiles before and after weight loss within one individual
resulted in numerical difficulties due to the large number of
random effects (54?) on the amplitude parameter to be
estimated. Therefore, the two occasions of one individual
were stratified using unique subject identifiers. Thereby
reducing the number of random effects within one indi-
vidual but losing the ability to identify intra-individual
variability between occasions before and after weight loss.
IIV was identified on, in order of inclusion, Baseline
(DOFV = -3702), A_0 (DOFV = -1611), kout (DOFV =
-642.0), SecretionSD (DOFV = -419) and Amplitude
(DOFV = -29). A 2 9 2 omega block was included after
covariate analysis to account for variance–covariance
correlation between the Baseline and Amplitude. A pro-
portional residual error structure was best fit for purpose.
The model fit was significantly better when using Eq. 3
(BIC = -3521.957) compared to the use of Eq. 4, where
exponent = 4 (BIC = -2772.223) or exponent = 2
(BIC = -1619.14).
Fig. 1 Observed growth hormone concentrations of three individuals over time of day
Fig. 2 Structural model including a zero-order baseline (kin) and
pulsatile secretion input (Sn(t)) with a first-order elimination rate (kout)
Table 1 Deconvolution analysis results reported as mean (sd), estimated by AutoDecon
Parameter Normal weight (n = 8) LBO UBO
Before WL (n = 8) After WL (n = 7) Before WL (n = 8) After WL (n = 7)
Pulse frequencya 15 (4) 17.8 (4.8) 17.4 (5.4) 14.6 (3.4) 16.4 (5.4)
Half-life (h) 0.245 (0.065) 0.233 (0.032) 0.26 (0.033) 0.235 (0.033) 0.247 (0.042)
Secretion width (h) 0.55 (0.118) 0.37 (0.168)* 0.44 (0.115) 0.37 (0.063)* 0.43 (0.086)*
Baseline secretion (mU/L/h) 0.666 (0.402) 0.636 (0.666) 0.738 (0.276) 0.288 (0.216)* 0.516 (0.372)
Amplitude 0.456 (0.234) 0.389 (0.227) 0.432 (0.132) 0.264 (0.202) 0.526 (0.337)
Pulse interval (h) 1.63 (0.49) 1.42 (0.54) 1.38 (0.38) 1.60 (0.42) 1.83 (1.45)
WL weight loss; LBO lower body obese; UBO upper body obese
a Total number of pulses in the 24 h period. * p\ 0.05 between normal weight and LBO/UBO group
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Covariate analysis
The estimation of a 24 h cosine function or a day/night
effect on Amplitude did not result in the improvement of
the OFV, indicating that no circadian rhythmicity could be
identified on this data. Inspection of the correlation plots of
the x2 distribution identified covariate relationships
between the distribution of Baseline, Amplitude and Se-
cretionSD with the TBW (%), as shown in Fig. 3. The
TBW (%) also showed a high degree of correlation
between the weight of a subject in which heavier subjects
had a lower percentage total body water. A power covariate
relationship showed to be superior over other tested rela-
tionships. The inclusion of this covariate relationship on
the Baseline, Amplitude and SecretionSD parameters
resulted in a significant decrease (DOFV = -48) in OFV.
Backward elimination did not result in the removal of a
covariate in this model. The previously observed covariate
correlations between the random effects were reduced to a
random scatter around 0 after inclusion of the covariate,
indicating that part of the identified variability could be
explained by the included covariate. The correlation plots
of TBW(%) with the x2 distribution of Baseline, Amplitude
and SecretionSD after inclusion of the covariate relation-
ship in the structural model, can be found in online
resource I.
Model evaluation
For visualization purposes, individual model fits over time,
for one individual per group, are depicted in Fig. 4. The
model predictions clearly show the adequate model fit of
the highly variable individual GH profiles in these indi-
viduals over a 24 h period. The individual tendency of all
data is well described, with observations close to line of
unity (individual observations vs. individual model pre-
dictions, Fig. 5). The individual observations vs. popula-
tion model predictions show a broad scatter around the line
of unity indicating an appropriate structural model com-
bined with high variability between and within individuals.
The CWRESI are normally distributed over the entire
range of population predictions and the majority of the
observations lie within the [-2,2] interval. Outliers iden-
tified in the CWRESI plots are resulting from mispredic-
tions of pulse times by the deconvolution analysis. The
highest CWRESI point results from the deconvolution
Fig. 3 Correlation plots of individual x2 estimates (solid colored circles) of a Amplitude, b Baseline, c SecretionSD and d weight (kg) versus the
total body water (%). Blue normal weight subjects; green lower body obese subjects; red upper body obese subjects (Color figure online)
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analysis not being able to fit a pulse at the last time points
where no information on the downward profile of the
concentration is available. The parameter estimates of the
final model are reported in Table 2. The population
parameters show low RSEs (ranging from 2 to 5%), indi-
cating high accuracy in the estimation of the population
parameters. The CV% was moderate ranging from 26.9 to
70.8% for most population parameters. High CV% was
identified for the A_0 and the j on Amplitude with a CV%
of 521 and 302% respectively. The high CV% for these
parameters originates from the differences in initial con-
centration (the possible occurrence of a pulse before the
start of the observation period) and the high variability in
pulse amplitudes between the separate pulses within one
individual. The condition number of the final model was
11.3, indicating no ill conditioning [23]. NPDE analysis
results can be found in online resource II. The NONMEM
code of the final deconvolution-analysis-informed
population model (FOCE?I, ADVAN = 13, TOL = 6,
SIGL = 6, NSIG = 3) can be found in online resource III.
Simulation
The simulated GH concentration–time profiles are depicted
in Fig. 6 and stratified on stimulatory (Fig. 6a) and inhi-
bitory (Fig. 6b) drug effects. The hypothetical drug was
administered after 6 h, indicated by the vertical dashed
black line. Simulations of the typical individual (black line,
09/0% effect) correspond with observed GH concentra-
tions in terms of pulse amplitude, pulse width and baseline
GH secretion for an individual with the mean TBW(%) of
44.7%. Stimulating the GH secretion showed a clear
increase in the GH concentrations which decreased back to
normal as can be seen by the color gradient. Inhibition of
the GH secretion by 100% reduced the GH concentration
back to baseline for the first hours after dosing. Thereafter,
Fig. 4 GH observations (mU/L) versus individual GH predictions of three individuals: a normal weight, b lower body obese and c upper body
obese subject on a semi-logarithmic scale. Black open dots: observations, solid colored line: individual model predictions (Color figure online)
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Table 2 Parameter estimates
for the deconvolution-analysis-
informed population model
Parameter Unit Estimate [RSE%] (CV%) Shrinkage (%)
H Amplitude mU/L/44.7% TBW 7.86 [3.25] –
H kout /h 2.78 [3.46] –
H SecretionSD h/44.7% TBW 0.182 [3.14] –
H Baseline mU/L/44.7% TBW 0.185 [4.52] –
H A_0 mU/L 1.05 [5.03] –
H Exponent Amplitude – 3.4 [2.1] –
H Exponent SecretionSD – 2.32 [3.15] –
H Exponent Baseline – 4.29 [4.29] –
x2 AmplitudeIIV – 0.22 (49.7) 12.8
x2 AmplitudeBOV-n – 2.32 (302) –
x2 kout – 0.0699 (26.9) 2.02
x2 SecretionSD – 0.0715 (27.2) 0.12
x2 Baseline – 0.406 (70.8) \0.01
x2 A_0 – 3.34 (521) 0.18
r2 proportional residual error – 0.106 5.61
RSE% relative standard error; CV% coefficient of variation; TBW total body water
Fig. 5 Goodness of fit plots for the deconvolution-analysis-informed
population model. a Population GH model predictions versus
observations b Individual GH model predictions versus observations
c CWRESI versus population predictions d CWRESI versus time of
day. Blue normal weight subjects; green lower body obese subjects;
red upper body obese subjects. Black diagonal line indicates line of
unity. Grey dashed horizontal lines indicate the [22,2] interval (Color
figure online)
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the GH secretion returned back to a pulsatile profile. The
inhibition of GH secretion by 75% showed reduced GH
concentrations but did not completely counter the pulsatile
secretion of GH in this scenario. The drug effect over time
is depicted in online resource IV.
The simulated clinical trial resulted in a total of 5800
observations which were then fitted to the true simulated
model structure (including the drug effect) and to a reduced
model structure (excluding the drug effect). Modeling the
GH secretion while excluding a drug effect resulted in an
OFV of -1871 points. The inclusion of an Emax relation-
ship for the drug effect resulted in a significant drop in
OFV (DOFV = -234). The re-estimated model parame-
ters are presented in Table 3 and are near identical to the
parameter values used for simulation of the clinical trial
data. The low RSE indicates high accuracy in the re-esti-
mation of the drug effect parameters given the true simu-
lated model. High shrinkage (51%) was observed on the
random effects of the EA50. The NONMEM model codes
used for simulation and re-estimation, including the GOF
plots for the re-estimated model, are provided in online
resource V.
Discussion
The developed method, using NLME modeling with
NONMEM, has proven to adequately describe variable
endogenous pulsatile GH concentration–time profiles in
women. This resulted in the identification of three
Table 3 Parameter estimates of
the simulated and the re-
estimated model
Parameter Simulated Re-estimated parameter estimates
[RSE%] (CV%)
Shrinkage (%)
H Emax -0.9 -0.929 [1.6] –
H EA50 3 3.16 [7.4] –
H c 5 5.04 [21] –
x2 EA50 0.01 0.0363 (19.2) 51
r2 proportional residual error 0.106 0.105 5.08
RSE% relative standard error; CV% coefficient of variation
Fig. 6 Simulated growth hormone profiles after administration of an
agonistic (a) or antagonistic (b) hypothetical drug. Dashed black
vertical line is the time of drug administration. Color gradient shows
the drug effect over time returning back to normal (black solid line)
(Color figure online)
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covariate relationships and the quantification of BOV and
IIV on the amplitude of pulses. In addition, simulations
have been performed to show hypothetical drug effects on
GH concentration–time profiles. The correct re-estimation
of the drug effect in the simulated clinical trial data shows
the applicability of this method in the analysis of variable
pulsatile data.
The RSEs of the population parameters were low
(\10%), indicating stable predictions of population
parameters. The CV% on A_0 and Amplitude were high,
which is in agreement with the observed high variability in
the observed concentration at time point 0 and between the
amplitude of pulses within an individual, respectively. The
high GH concentrations at the first measurement indicate
that sampling should be performed at several pre-dose time
points to be able to quantify GH pulses that may have
occurred before dose administration. The population half-
life of GH was estimated as 15 min (ln(2)/kout) in this
population and can be compared with the half-life reported
in literature [27–29]. No circadian rhythmicity was iden-
tified in this population. This could be due to potential
differences between men and women in regards to noc-
turnal GH secretion [30].
The study of Pijl et al. [19] resulted in the identification
of a stratification between the GH secretion in UBO
compared to LBO and normal weight subjects. The
deconvolution analysis performed in this study did also
result in the identification of a lower baseline secretion in
UBO subjects before weight loss. No changes in the pulse
amplitude were identified between groups. In this study,
significant continuous covariate relationships have been
identified in which the total body water was the best
covariate explaining the IIV for Baseline, Amplitude and
SecretionSD. Furthermore, the possibility to follow the GH
concentration over time in a NLME model increased the
information that is retrieved from these dense sampled
observations.
During model development, it was required to stratify
the two occasions, before and after weight loss, of one
individual with unique identifiers to prevent numerical
instability of the model. This resulted in the loss of esti-
mation of the intra-individual variability between these
separate occasions. Due to the high variability in the GH
profiles that were observed between the occasions before
and after weight loss, the long duration between the
occasions (up to 6 months) and the nature of this paper to
establish a new quantification method using NLME mod-
eling, this stratification was deemed appropriate.
The Gaussian shaped events that are fitted in deconvo-
lution analysis have the advantage to be applicable on a
wide range of pulsatile compounds [31, 32]. However, this
generalization inherently brings the disadvantage that no
mechanistic information of the biological regulation of the
compound is incorporated in the structural model. Espe-
cially when multiple components are involved in the reg-
ulation of the secretion, e.g. stimulation by growth
hormone releasing hormone and inhibition by somatostatin
in the case of GH, more mechanistic insights can be ben-
eficial in explaining the variability between individuals and
possible extrapolation to disease states.
Compared to previously used non-compartmental anal-
ysis, the current analysis enables the quantification of a
drug effect targeting GH secretion over time in which an
Emax or other PK/PD relationships can be determined using
NLME in NONMEM. The correct estimation of the PK/PD
relationship parameters on a pulsatile compound will be
mainly dependent on 3 components: (1) the frequency of
sampling, which is critical for compounds with a short half-
life [11], (2) the duration of the observation period should
preferably include the on- and offset of the drug effect and
(3) the expected variability in response should be taken into
account when choosing the study sample size.
The method proposed in this study can be applied to
analyze or simulate different pulsatile profiles. From the
analysis step, information can be obtained on the pulsatile
behavior (pulse frequency, width and amplitude) in a
population and on the PK/PD relationship. From a clinical
perspective, this provides more insight in the relationship
between the pulsatile secretion of a compound and the
effect that a drug has over time compared to differences in
the AUC or Cmax when comparing placebo with treated
individuals. The provided simulations in this study visu-
alize what effect hypothetical drugs can have on a pulsatile
profile. This was simulated for drugs having agonistic or
antagonistic properties. After administration of an agonistic
compound with an Emax of 10, the maximum GH concen-
tration reached was *50 mU/L. These simulations are
physiologically plausible since the simulated concentration
are in agreement with data from acromegalic patients in
which GH concentrations are in the same range [33]. The
provided antagonistic simulations suggest a reduction to
baseline after fully blocking the pulsatile secretion
(Emax = -1). These antagonistic drug simulations
(Fig. 6b) correspond with the clinical response as shown
after treatment with Ocreotide, a somatostatin analogue,
which can completely block the endogenous pulsatile
secretion of GH for 5 h after dosing [7]. Blocking the pulse
amplitude by 75% lowers the pulsatile GH secretion but
did not fully block the pulsatile profile. The pulse interval
can be changed in the model code to simulate a different
pulse frequency, including variability on the pulse interval.
Simulations incorporating the established Emax and/or EC50
values of a known drug on GH secretion can then be used
to support dose selection or to investigate novel dosing
regimens for the studied drug. The observation period of a
study can be expanded if simulations show that the full
398 J Pharmacokinet Pharmacodyn (2017) 44:389–400
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effect is reached at a later stage than expected (e.g. indirect
response or delayed release formulation of the drug) or that
a fast offset of the drug effect suggests the need for more
selective monitoring for multiple hours at an early stage
compared to a full 24 h period.
Instead of using ‘simple’ summary statistics (mean,
AUC, Cmax) for complex and variable pulsatile profiles, it
is now possible to quantify and model a pulsatile profile
over time and to identify what effect a potential drug has
on the secretion. This two-step deconvolution-analysis-in-
formed population pharmacodynamic model enables the
possibility to analyze highly variable pulsatile profiles with
a NLME PK/PD model in NONMEM.
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